Novo Nordisk(US:NVO) Huan Qiu Wang Zi Xun·2025-11-27 10:53Core Insights - Novo Nordisk announced that its recent trials of semaglutide did not slow the progression of Alzheimer's disease [2][3] - Semaglutide, a GLP-1 analog, was initially approved for blood sugar reduction and later for weight management, gaining significant attention as a "weight loss miracle drug" [2] - The trials included over 3,800 adult patients receiving standard Alzheimer's treatment, aiming to evaluate semaglutide's efficacy compared to a placebo [2] Group 1 - The trials showed that while semaglutide was safe and effective in improving Alzheimer's-related biomarkers, it did not delay disease progression [2] - Novo Nordisk's Chief Scientific Officer stated that the likelihood of GLP-1 drugs being effective for Alzheimer's treatment was considered very low [3] - The company will terminate a one-year extension trial, with results pending peer review and set to be presented at an upcoming scientific conference [3] Group 2 - Ongoing research into the effects of GLP-1 drugs on Alzheimer's disease is expected, with experts suggesting these drugs may be more suitable for prevention rather than treatment of diagnosed cases [3] - The Alzheimer's Association in the U.S. has indicated it will continue research involving GLP-1 [3]